Insulin and endothelin in the acute regulation of adiponectin in vivo in humans

Obesity Research

Volumn 13, Issue 3, 2005, Pages 582-588

  Brame, Lori A ^a   Considine, Robert V ^a   Yamauchi, Mikako ^a   Baron, Alain D ^a,b   Mather, Kieren J ^a  

^a INDIANA UNIVERSITY   (United States)

^b AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Adiponectin; Endothelin; Insulin; Regulation

Indexed keywords

ADIPONECTIN; CYCLO(TRP ASP PRO VAL LEU); CYCLO(TRP-ASP-PRO-VAL-LEU); CYCLOPEPTIDE; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; INSULIN; SIGNAL PEPTIDE;

ADOLESCENT; ADULT; ARTICLE; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GLUCOSE CLAMP TECHNIQUE; HOMEOSTASIS; HUMAN; MALE; MIDDLE AGED; OBESITY; PHYSIOLOGY;

ADIPONECTIN; ADOLESCENT; ADULT; ENDOTHELIN-1; ENDOTHELINS; FEMALE; GLUCOSE CLAMP TECHNIQUE; HOMEOSTASIS; HUMANS; INSULIN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; OBESITY; PEPTIDES, CYCLIC; RECEPTORS, ENDOTHELIN;

EID: 22844434460     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2005.62     Document Type: Article

References (38)

1. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci. 1999;892:146-54.
2. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to Clq, produced exclusively in adipocytes. J Biol Chem. 1995;270:26746-9.
3. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79-83.
4. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930-5.
5. Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 2002;51:2968-74.
6. Hu E, Liang P, Spiegeltnan BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 1996;271: 10697-703.
7. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factoralpha expression. Diabetes. 2003;52:1779-85.
8. Statnick MA, Beavers LS, Conner LJ, et al. Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res. 2000;1:81-8.
9. Yang WS, Chen MH, Lee WJ, et al. Adiponectin mRNA levels in the abdominal adipose depots of nondiabetic women. Int J Obes Relat Metab Disord. 2003;27:896-900.
10. Motoshima H, Wu X, Sinha MK, et al. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab. 2002;87:5662-7.
11. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2002; 290:1084-9.
12. Clarke KJ, Zhong Q, Schwartz DD, Coleman ES, Kemppainen RJ, Judd RL. Regulation of adiponectin secretion by endothelin-1. Biochem Biophys Res Commun. 2003;312: 945-9.
13. Fasshauer M, Kralisch S, Klier M, et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2003; 301:1045-50.
14. Mohlig M, Wegewitz U, Osterhoff M, et al. Insulin decreases human adiponectin plasma levels. Harm Metab Res. 2002;34:655-8.
15. Hirose H, Kawai T, Yamamoto Y, et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism. 2002;51:314-7.
16. Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferator- activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care. 2002;25:376-80.
17. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50: 2094-9.
18. Ishibashi KI, Imainura T, Sharma PM, Huang J, Ugi S, Olefsky JM. Chronic endothelin-1 treatment leads to heterologous desensitization of insulin signaling in 3T3-L1 adipocytes. J Clin Invest. 2001;107:1193-202.
19. Ferri C, Bellini C, Desideri G, et al. Circulating endothelin-1 levels in obese patients with the metabolic syndrome. Exp Clin Endocrinol Diabetes. 1997;2(Suppl 105):38-40.
20. Irving RJ, Noon JP, Watt GC, Webb DJ, Walker BR. Activation of the endothelin system in insulin resistance. QJM. 2001;94:321-6.
21. Piatti PM, Monti LD, Galli L, et al. Relationship between endothelin-1 concentration and metabolic alterations typical of the insulin resistance syndrome. Metabolism. 2000;49:748-52.
22. Mather KJ, Mirzamohammadi B, Lteif A, Steinberg HO, Baron AD. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes. 2002;51:3517-23.
23. Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation. 2002; 106:1783-7.
24. Wilkes JJ, Hevener A, Olefsky J. Chronic endothelin-1 treatment leads to insulin resistance in vivo. Diabetes. 2003; 52:1904-9.
25. Ottosson-Seeberger A, Lundberg JM, Alvestrand A, Ahlborg G. Exogenous endothelin-1 causes peripheral insulin resistance in healthy humans. Acta Physiol Scand. 1997;161: 211-20.
26. Jiang ZY, Zhou QL, Chatterjee A, et al. Endothelin-1 modulates insulin signaling through phosphatidylinositol 3-ki-nase pathway in vascular smooth muscle cells. Diabetes. 1999;48:1120-30.
27. Imamura T, Ishibashi K, Dalle S, Ugi S, Olefsky JM. Endothelin-1-induced GLUT4 translocation is mediated via Galpha(q/11) protein and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. J Biol Chem. 1999;274:33691-5.
28. Ishibashi K, Imamura T, Sharma PM, Ugi S, Olefsky JM. The acute and chronic stimulatory effects of endothelin-1 on glucose transport are mediated by distinct pathways in 3T3-L1 adipocytes. Endocrinology. 2000;141:4623-8.
29. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-23.
30. Hafizi S, Allen SP, Goodwin AT, Chester AH, Yacoub MH. Endothelin-1 stimulates proliferation of human coronary smooth muscle cells via the ET(A) receptor and is co-mitogenic with growth factors. Atherosclerosis. 1999;146:351-9.
31. Maguire JJ, Davenport AP. ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol. 1995;115:191-7.
32. Bohm F, Ahlborg G, Pernow J. Endothelin-1 inhibits endothelium-dependent vasodilatation in the human forearm: reversal by ETA receptor blockade in patients with atherosclerosis. Clin Sci (Land). 2002;102:321-7.
33. Polak K, Petternel V, Luksch A, et al. Effect of endothelin and BQ123 on ocular blood flow parameters in healthy subjects. Invest Ophthalmol Vis Sci. 2001;42:2949-56.
34. Bohm F, Pernow J, Lindstrom J, Ahlborg G. ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men. Clin Sci (Land). 2003;104:143-51.
35. Newby DE, Flint LL, Fox KA, Boon NA, Webb DJ. Re duced responsiveness to endothelin-1 in peripheral resistance vessels of patients with syndrome X. J Am Coll Cardiol. 1998;31:1585-90.
36. Spratt JC, Goddard J, Patel N, Strachan FE, Rankin AJ, Webb DJ. Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. Br J Pharmacol. 2001;134:648-54.
37. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vase Biol. 2000;20: 1595-9.
38. Yamamoto Y, Hirose H, Saito I, et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lord). 2002;103:137-42.